Immune checkpoint inhibitors (ICIs) are immunomodulatory antibodies that intensify the host
immune response, thereby leading to cytotoxicity. The primary targets for checkpoint …

Simple Summary Immune-based treatment strategies, which include immune checkpoint
inhibition, have recently become a new frontier for the treatment of B-cell-derived lymphoma …

To evade elimination by the host immune system, tumor cells commonly exploit
physiological immune checkpoint pathways, restraining efficient anti-tumor immune cell …

Classical Hodgkin lymphoma (cHL) has been identified with universal genetic alterations of
chromosome 9p24. 1, which contains PD-L1/PD-L2 genes. The amplification of 9p24. 1 is …

Malignant lymphoma (ML) is a common hematological malignancy with many subtypes.
Patients with ML usually undergo traditional treatment failure and become relapsed or …

Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …

Advances in Cancer immunotherapy in the past few years include the development of
medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 …

The immune system is the core defense against cancer development and progression.
Failure of the immune system to recognize and eliminate malignant cells plays an important …

Immune checkpoint blockade has revolutionized the treatment of cancer, with impressive
responses seen in a broad variety of tumor types. Blockade of immune checkpoints and …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …